Elafin drives poor outcome in high grade serous ovarian cancers and basal-like breast tumors
Labidi-Galy, S. Intidhar
Davidowitz, Rachel A.
Mills, Gordon B.
MetadataShow full item record
CitationLabidi-Galy, S. I., A. Clauss, V. Ng, S. Duraisamy, K. M. Elias, H. Piao, E. Bilal, et al. 2014. “Elafin drives poor outcome in high grade serous ovarian cancers and basal-like breast tumors.” Oncogene 34 (3): 373-383. doi:10.1038/onc.2013.562. http://dx.doi.org/10.1038/onc.2013.562.
AbstractHigh grade serous ovarian carcinoma (HGSOC) and basal-like breast cancer (BLBC) share many features including TP53 mutations, genomic instability and poor prognosis. We recently reported that Elafin is overexpressed by HGSOC and is associated with poor overall survival. Here, we confirmed that Elafin overexpression is associated with shorter survival in 1000 HGSOC patients. Elafin confers a proliferative advantage to tumor cells through activation of the MAP kinase pathway. This mitogenic effect can be neutralized by RNA interference, specific antibodies, and a MEK inhibitor. Elafin expression in patient-derived samples was also associated with chemoresistance and strongly correlates with bcl-xL expression. We extended these findings into examination of 1100 primary breast tumors and six breast cancer cell lines. We observed that Elafin is overexpressed and secreted specifically by BLBC tumors and cell lines, leading to a similar mitogenic effect through activation of the MAP kinase pathway. Here too, Elafin overexpression is associated with poor overall survival, suggesting that it may serve as a biomarker and therapeutic target in this setting.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:17820911
- HMS Scholarly Articles